COVID-19 Healthcare Valuation Implications

Presented by: Todd A. Zigrang, MBA, MHA, FACHE, CVA, ASA Jessica L. Bailey-Wheaton, Esq.

NACVA and the CTI's

2021 Business Valuation & Financial Litigation Hybrid & Virtual Super Conference December 13-17, 2021



DISCLAIMER

This work is under copyright and all rights are reserved to the Authors. No part of this work covered by the copyrights herein may be reproduced or copied in any form or by any means, whether graphically, electronically, or mechanically, including by means of photocopying, audio/video recording, or information storage and retrieval of any kind, without the express written permission of the Consultants' Training Institute® (CTI®), the National Association of Certified Valuators and Analysts® (NACVA®), and the presenter (collectively "Authors").

The information contained in this presentation and accompanying materials ("Information") is intended only for illustrative or general training purposes. Although the Authors have made reasonable efforts to provide authoritative and accurate information about the subjects covered, the Information is provided with the understanding that the Authors are not engaged in rendering legal, accounting, or other professional service or advice. If legal or other expert advice is required, the services of an appropriate professional person should be sought.

The Authors make no representation or warranty concerning the accuracy or correctness of the Information or concerning its usefulness or fitness for any particular purpose. The Information may not be applicable or suitable for the reader/viewer's specific needs or circumstances. Readers/viewers should not use or rely on this Information as a substitute for consultation with qualified professionals in the subject matter presented here.

Although the Information has been carefully compiled from sources believed to be reliable, the accuracy of the Information is not guaranteed. It is neither intended nor should it be construed as legal, accounting, and/or tax advice, nor as an opinion provided by CTI, NACVA, the presenter, or the presenter's firm.

The Authors specifically disclaim any liability for loss or risk incurred as a consequence of the use, either directly or indirectly, of the Information or for any advice contained in the presentation of the Information. The presenter's opinion may not reflect those of CTI or NACVA or their policies, other instructors, or materials.

The opinions or positions of the Authors as stated in the Information may vary depending on the facts and policies surrounding the actual or hypothetical situations described. Changes in facts and/or policies may result in conclusions different than those stated herein. The information provided herein is not intended to reflect the opinions or positions of the Authors in relation to any specific case, but, rather, to be illustrative for educational purposes. The user is cautioned that this course is not all inclusive.

© 2021 National Association of Certified Valuators and Analysts (NACVA). All rights reserved. • 5217 South State Street, Suite 400, SLC, UT, 84107.



The Consultants' Training Institute (CTI) is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be submitted to the National Registry of CPE Sponsors through its website: www.nasbaregistry.org.



Presenter Bio

Todd A. Zigrang, MBA, MHA, FACHE, CVA, ASA is the President of **HEALTH CAPITAL CONSULTANTS** (HCC), where he focuses on the areas of valuation and financial analysis for hospitals, physician practices, and other healthcare enterprises. Mr. Zigrang has over 25 years of experience providing valuation, financial, transaction and strategic advisory services nationwide in over 2,000 transactions and joint ventures involving acute care hospitals and health systems; physician practices; ambulatory surgery centers; diagnostic imaging centers; accountable care organizations, managed care organizations, and other third-party payors; dialysis centers; home health agencies; long-term care facilities; and, numerous other ancillary healthcare service businesses. Mr. Zigrang is also considered an expert in the field of healthcare compensation for physicians, executives and other professionals.



Mr. Zigrang is the co-author of the "Adviser's Guide to Healthcare – 2nd Edition" (AICPA, 2015), numerous chapters in legal treatises and anthologies, and peer-reviewed and industry articles such as: The Guide to Valuing Physician Compensation and Healthcare Service Arrangements (BVR/AHLA); The Accountant's Business Manual (AICPA); Valuing Professional Practices and Licenses (Aspen Publishers); Valuation Strategies; Business Appraisal Practice; and, NACVA QuickRead. Additionally, Mr. Zigrang has served as faculty before professional and trade associations such as the American Bar Association (ABA); the National Association of Certified Valuators and Analysts (NACVA); the American Society of Appraisers (ASA); Medical Group Management Association (MGMA); Physician Hospitals of America (PHA); the Institute of Business Appraisers (IBA); the Healthcare Financial Management Association (HFMA); and, the CPA Leadership Institute.



Presenter Bio

Jessica L. Bailey-Wheaton, Esq., serves as Senior Vice President & General Counsel of **HEALTH CAPITAL CONSULTANTS** (HCC), where she focuses on the areas of project management and consulting services related to the impact of federal and state regulations on healthcare transactions. In that role, she provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises, assets, and services. Additionally, Ms. Bailey-Wheaton heads HCC's Certificate of Need (CON) and regulatory consulting service line.

Ms. Bailey-Wheaton is the co-author of numerous peer-reviewed and industry articles in publications such as: The Health Lawyer (ABA); Physician Leadership Journal (AAPL); The Journal of Vascular Surgery; The Value Examiner (NACVA); QuickRead (NACVA). She has previously presented before NACVA, the ABA, and the National Society of Certified Healthcare Business Consultants (NSCHBC).

She serves on the editorial boards of NACVA's *QuickRead* and the American Health Law Association's (AHLA's) *Journal of Health & Life Sciences Law*. Additionally, she serves as Vice Chair for Educational Programming with AHLA's Fair Market Value Affinity Group; Liaison for the Young Lawyers Division (YLD) Health Law Committee; and, Vice Chair for the ABA HLS Membership Committee. Ms. Bailey-Wheaton is a member of the Missouri and Illinois Bars and holds a Juris Doctorate (JD), with a concentration in Health Law, from Saint Louis University School of Law.





Session Overview

- Impact of COVID-19 on Healthcare Transactions
- Impact of COVID-19 on the 4 Pillars of Healthcare Valuation
 - Regulatory
 - Reimbursement
 - Competition
 - Technology

NACVA

- Impact of COVID-19 on the Valuation of Healthcare Enterprises and Assets
- Impact of COVID-19 on the Valuation of Healthcare Services

Healthcare M&A Activity Impact of COVID-19

Quarterly U.S. Healthcare M&A Activity for Transactions Closed, **Aggregate Transaction Value, and Number Of Deals** Number of deals Aggregate Transaction Value (\$BB) \$200 500 \$174.3 \$180 450 \$160 \$150.6 400 deal \$140 350 \$120 300 d \$100 250 Number \$91.7 \$80 200 \$69.6 \$68.8 \$58.7 \$54.2 \$51.9 \$60 150 \$36.9 \$35.9 \$32.1 \$40 \$29.8 \$26.3 \$14.9 \$17.7 \$20 \$0 Q1-2018 02-2018 Q4-2018 Q1-2019 02-2019 Q4-2019 Q1-2020 02-2020 Q4-2017 Q3-2019 Q1-2021 Q3-2018 03-2020 Q4-2020 02-2021 03-2017

> Source: "Healthcare M&A Update: H1 2021" Baker Tilly Capital, available at: https://prismic-io.s3.amazonaws.com/bakertilly-www/bd4cad7b-0169-4dfb-8bcc-53fab233c1ff_2021_h1-healthcare-ma-update.pdf (Accessed 12/9/21).




Healthcare M&A Activity Impact of COVID-19

- COVID-19 has a continuing impact on:
 - Horizontal Consolidation Strategies
 - Vertical Integration Strategies
 - Risk Mitigation Strategies
 - Healthcare Services Offered
 - Non-Traditional Healthcare Providers
 - Due Diligence



Impact on the Valuation of Healthcare Enterprises, Assets, and Services





COVID-19 Impact on Healthcare Valuation Regulatory Considerations

- Federal legislation affecting healthcare providers
- > Regulatory Waivers & Relaxations
 - Telehealth Services During Certain Emergency Periods Act
 - Anti-Kickback Statute & Stark Law Blanket Waivers
- Compliance issues after end of waivers & relaxations



COVID-19 Impact on Healthcare Valuation Reimbursement Considerations

- Cancelled or rescheduled elective procedures
- Potential changes in payor mix
- Simultaneous changes to the Medicare Physician Fee Schedule
- Felehealth services



COVID-19 Impact on Healthcare Valuation Competition Considerations

- > Healthcare workforce issues
- Potential acceleration in shift of healthcare delivery to outpatient settings
- Technologically-inclined providers positioned to succeed during the pandemic
- Changes in competition driving mergers and acquisitions



COVID-19 Impact on Healthcare Valuation Technology Considerations

- Information technology solutions such as web/cloud-based EMRs have seen a significant boost in uptake
- Advancements in virtual health, drones and robotics to reduce person-to-person interaction
- Temporary expanded use of healthcare technology will it continue?



Valuation Approaches for Healthcare Enterprises, Assets, & Services

Factors to Consider

- Valuation Date and Subsequent Events
- Financial Projections
- Valuation Purpose



Valuation Approaches for Healthcare Enterprises, Assets, & Services

Valuation Approaches

- Income Approach considerations
- Market Approach considerations
- Asset Approach considerations



Valuation Approaches for Healthcare Enterprises, Assets, & Services

Income Approach

- Cash Flow or other Economic Benefits of Ownership
- Capital Considerations



Income Approach

- Risk Adjusted Rates of Return
- Valuation Adjustments
- COVID-19 Premium



- Consideration of Market Approach-based Valuation Methodologies
 - Applicability of Historical Transaction Multiples
 - Applicability of Selected Economic Benefits of Ownership (Earnings Stream)



- Consideration of Asset Approach-based Valuation Methodologies
 - Premise of Value Considerations
 - Healthcare Business Valuation Considerations



> Impact on Specific Healthcare Industry Subsectors

- Hospitals
- Physician Practices
- Ambulatory Surgery Centers (ASCs)
- Long-Term Care
- Hospice and Home Health

- Payors
- Pharmaceutical Companies
- Dialysis Centers
- Medical Device and Supply Companies
- Ancillary Service Providers



Hospitals

- Impact of COVID-19
- Merger and Acquisition Activity
- Short-Term Outlook
- Valuation Implications



- > Physician Practices
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



- > Ambulatory Surgical Centers (ASCs)
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



- Long-Term Care
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



- Hospice and Home Health
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



Payors

- Impact of COVID-19
- Merger and Acquisition Activity
- Short-Term Outlook
- Valuation Implications



- > Pharmaceutical Companies
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



- Dialysis Centers
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



- Medical Device and Supply Companies
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



- > Ancillary Service Providers
 - Impact of COVID-19
 - Merger and Acquisition Activity
 - Short-Term Outlook
 - Valuation Implications



Valuation of Healthcare Services Impact of COVID-19

- Purpose of Engagements
- Similarity to Business Valuation
 - Fair Market Value
 - Regulatory Requirements
 - Valuation Principles

NACVA

- Valuation Methodologies
- Differences from Business Valuation

Compensation Arrangements Purpose of Engagements

- > Types of Service Arrangements
 - Physician Compensation
 - Employment
 - Provider Services
 - Non-Clinical

NACVA

CTI

- Management Services Agreements (MSAs)
- Co-Management Service Arrangements
- Telemedicine Service Agreements

Compensation Arrangements Comparison to Business Valuation

- Fair Market Value
- Regulatory Requirements
- Valuation Principles
- Valuation Methodologies



Income Approach

- Applications
- Advantages
- Limitations
- Considerations Resulting from COVID-19



- Cost Approach
 - Applications
 - Advantages
 - Limitations
 - Considerations Resulting from COVID-19



Market Approach

- Applications
- Advantages
- Limitations




Market Approach


NACVA

- Effect of COVID-19 on Physician Compensation and Productivity from 2020 to 2021
 - Changes in Annual Compensation
 - Changes in wRVU Productivity
 - Changes in Compensation per wRVU

> Annual Cash Compensation




Note: Survey data is for Family Medicine (without OB) results from survey published by MGMA.



Note: Survey data is for General Cardiology (Noninvasive) results from survey published by MGMA.



> Annual wRVU Productivity




Note: Survey data is for Family Medicine (without OB) results from survey published by MGMA.

Note: Survey data is for General Cardiology (Noninvasive) results from survey published by MGMA.



Compensation per wRVU Productivity



Survey data is for General Cardiology (Noninvasive) results from survey published by MGMA.



Family Medicine and Cardiology

	2016	2017	2018	2019	2020
Family Medicine					
Median Annual Cash Compensation	\$233,770	\$236,935	\$247,253	\$254,665	\$264,698
Percentage change from prior year		1.35%	4.35%	3.00%	3.94%
Median wRVU Productivity	4,850	4,804	4,914	4,936	4,388
Percentage change from prior year		-0.95%	2.29%	0.45%	-11.10%
Median Compensation to wRVU Productivity	\$49.49	\$50.29	\$51.14	\$51.70	\$59.69
Percentage change from prior year		1.62%	1.69%	1.10%	15.45%
Cardiology					
Median Annual Cash Compensation	\$470,610	\$479,882	\$515,635	\$529,027	\$521,248
Percentage change from prior year		1.97%	7.45%	2.60%	-1.47%
Median wRVU Productivity	7,325	7,683	7,644	8,047	6,820
Percentage change from prior year		4.89%	-0.51%	5.27%	-15.25%
Median Compensation to wRVU Productivity	\$60.80	\$60.73	\$63.21	\$63.67	\$73.05
Percentage change from prior year		-0.12%	4.08%	0.73%	14.73%



Other Considerations

NACVA

• Changes to the Medicare Physician Fee Schedule (MPFS)

Changes in the 2021 MPFS

- Increase in wRVUs for most office visit Evaluation & Management (E&M) Codes
- Reduction in the conversion factor to \$34.89
- Addition of add-on codes (G2212 and G2211) to recognize extended office visit time and account for qualified, severe or complex chronic conditions

Other Considerations

NACVA

CTI

• Changes to the Medicare Physician Fee Schedule (MPFS)

Changes in the 2022 MPFS

- Reduction in the conversion factor to \$33.58, due to end of the temporary 3.75% payment increase for 2021, as a budget neutrality adjustment
- If the Government decides to waive the budget neutrality payment reduction, the conversion factor will remain unchanged at \$34.89

Other Considerations

Changes to the Medicare Physician Fee Schedule (MPFS)

	Changes under 2021 MPFS from 2020			Changes under 2022 MPFS from 2021		
	Change in Work RVUs	Change in Payment	Change in Payment with Expiration of 3.75% CF Increase CF = \$33.58	Change in Payment with Expansion of 3.75% CF Increase CF = \$34.89		
Family Medicine	8.00%	13.00%	-1.60%	2.10%		
Cardiology	1.00%	1.00%	-4.70%	-1.20%		
General Surgery	-4.00%	-6.00%	-3.80%	-0.20%		
Internal Medicine	2.00%	4.00%	-2.40%	1.20%		
Neurosurgery	-4.00%	-6.00%	-3.20%	0.50%		
Ophthalmology	-4.00%	-6.00%	-3.30%	0.40%		
Orthopedic Surgery	-3.00%	-4.00%	-2.70%	1.00%		
Obstetrics/ Gynecology	4.00%	7.00%	-3.00%	0.70%		
Pediatrics	4.00%	6.00%	-2.90%	0.80%		
Psychiatry	4.00%	7.00%	-3.10%	0.50%		
Vascular Surgery	-2.00%	-6.00%	-11.40%	-8.10%		

"Medicare Physician Payment Schedule: Detailed Summary' American Medical Association (AMA), 2020, https://www.amaassn.org/system/files/2020-12/2021-pfs-qpp-final-rule.pdf "2022 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) Proposed Rule Summary Physiciar Payment Schedule, AMA, 2021, https://www.amaassn.org/system/files/2022-pfs-qpp-proposed-rule.pdf



Valuation of Healthcare Services Impact of COVID-19

- > Other Considerations
 - Emergency Departments and Intensive Care Units
 - Hazard Pay

NACVA

- Non-Essential Services
- Advanced Practice Clinicians
- Acceleration to Value-Based Reimbursement

Conclusion

- Return to fundamental valuation analysis frameworks
- > Evaluate the specific facts and circumstances for each valuation assignment
- Evaluate whether the impact of COVID-19 was known or knowable as of the valuation date
- Consider what the short-term and long-term impacts of COVID-19 are on the enterprise, assets, or service
- Valuations may need to be updated or modified as the impact of COVID-19 continues to evolve
- Keep clients informed of the impacts that COVID-19 may have on the valuation assignment



Conclusion

- While the focus of healthcare providers and regulators is, appropriately, on the access to and delivery of care to those impacted by the COVID-19 outbreak, the regulatory scrutiny related to fraud and abuse issues will persist
- This current uncertainty creates a plausible scenario wherein a valuation professional may be required to deviate from industry normative benchmark data to account for those specific facts and circumstances related to a given transaction
- > As a result, valuation professionals opining on these transactions should:
 - Utilize an evidence-driven methodology that includes both qualitative and quantitative assessments of the specific facts and circumstances related to the transaction
 - Document their consideration of these facts and circumstances
 - Articulate their ultimate applicability to the transaction in support of their opinion

NACVA an CTI 2021 B

Questions and Answers



